Case Discussions in HSCT-TMA: Integrating New Data to Improve Patient Outcomes

Release Date: March 29, 2021
Expiration Date: March 29, 2022

Activity Overview

This online, on-demand, virtual symposium brings together renowned experts in the treatment of transplant-associated thrombotic microangiopathy (TA-TMA) to address diagnostic challenges, and to guide clinicians in incorporating new standards of patient care as new therapies are developed and potentially introduced into the treatment paradigm. The activity includes case-based discussions that demonstrate the clinical significance of dysregulated complement activation in relation to TA-TMA.

This educational activity is an archive of a live virtual symposium held on February 9, 2021.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Omeros Corporation.

Target Audience

This educational program is directed toward hematologists, medical oncologists, researchers, and investigators who treat or are interested in the treatment of hematologic malignancies. Other allied health care professionals, including nurse practitioners, physician assistants, and nurses involved in the treatment and management of patients with hematologic malignancies, will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Review current diagnostic criteria for hematopoietic stem cell transplant–associated thrombotic microangiopathy (HSCT-TMA) and ways to differentiate it from other stem cell transplant–associated complications with overlapping symptoms
• Assess the role of dysregulated complement activation in the pathogenesis of HSCT-TMA
• Discuss the rationale concerning the application of complement targeted therapies, including MASP-2 inhibitors, in the treatment of HSCT-TMA
• Evaluate recent clinical trial data concerning the effectiveness of emerging therapies in the treatment of HSCT-TMA

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Sergio A. Giralt, MD, FACP
Professor of Medicine
Weill Cornell Medicine
Melvin Berlin Family Chair in Multiple Myeloma
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Actinium Pharmaceuticals, Amgen, Bristol Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, Pfizer, Sanofi; Other: Scientific Advisory Board: Actinium Pharmaceuticals, Amgen, Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Pharmaceuticals, Jazz Pharmaceuticals.

Christopher Dandoy, MD, MS
Assistant Professor of Clinical Pediatrics
Division of Bone Marrow Transplantation and Immune Deficiency
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Disclosures: Consultant: Omeros Corporation.

Sonata Jodele, MD
Research Professor of Pediatrics
Division of Bone Marrow Transplantation and Immune Deficiency
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Disclosures: Grant Research Support: National Institutes of Health–funded R01 study (eculizumab supplied by Alexion Pharmaceuticals at no charge to study subjects); Consultant: Omeros Corporation; Other: United States Patent No: US 10,815,296 B2.

Jeffrey Laurence, MD
Professor of Medicine
Weill Cornell Medicine
New York, NY

Disclosures: Grant Research Support: Omeros Corporation; Consultant: Omeros Corporation.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.